Chinese-Origin Bifidobacterium breve XA-2103 Granted National Invention Patent, Set for Commercialization

In recent years, scientific research has discovered,Gut microbiota plays a key role in metabolic regulation.Xbiome, based on the latest academic achievements and relying on the advanced strain screening capabilities of its AI microbiome research platform, has developed Bifidobacterium breve XA-2103. Comprehensive mechanistic studies and functional validations demonstrate that this strain can alleviate colitis and restore intestinal health.

According to the introduction, XA-2103 is"Indigenous bacteria" from the intestines of healthy individuals in China,Isolated from the "super donor" in Xbiome's FMT donor bank, who is physically healthy and has excellent microbiota functional data. Currently, this strain is preserved at the Institute of Microbiology, Chinese Academy of Sciences, with the preservation number CGMCC No. 26611. The patent approved this time is titled "A Strain of Bifidobacterium breve and Its Application".

A series of studies on the safety of the XA-2103 strain have been carried out by the "Microecological Pharmaceutical Joint Laboratory" co-established by SIAT (Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences) and Xbiome.This strain has passed the virulence factor and resistance gene testing according to international standards, showing no potential risks. It exhibits excellent performance in terms of safety and stability, allowing consumers to use probiotic products containing XA-2103 with confidence.

According to the patent application materials submitted by Xbiome for XA-2103, the anti-colitis capability of this strain has been verified through multi-dimensional experiments.In animal experiments, this strain significantly improved weight loss caused by enteritis, reduced the disease activity index of inflammatory bowel disease, and particularly restored the relative and absolute length of the colon, improving the histopathological structure of the colon.Therefore, XA-2103 can directly alleviate the symptoms of colitis and has a positive therapeutic effect on inflammatory bowel disease.

In further studies on the scientific mechanisms of strains, the Xbiome scientific team discoveredThe XA-2103 strain "intelligently" protects the gut through two scientific mechanisms: "maintaining intestinal barrier integrity + modulating immunity and reducing inflammation," achieving precise regulation of metabolism.

In models with impaired intestinal epithelial integrity, XA-2103 upregulated the expression of tight junction proteins, reduced the permeability of intestinal epithelial cells, and repaired the native intestinal barrier. Additionally, studies found that XA-2103 decreased the secretion of cellular inflammatory factors, inhibited the secretion of inflammatory factors in the intestine, and modulated intestinal immune balance.

XA-2103 is one of the "star strains" discovered and developed by Xbiome using its self-built AI microbiome research and industrial development platform. The Xbiome scientific team introduced that the company has independently constructed a strain library.The XBIOME GUT BIOBANK (XGB), extracted from the intestines of healthy individuals in ChinaMore than 16,000 strains。

During the development of XA-2103, the team screened over 100 strains through sequence alignment and protein structure modeling, precisely identifying more than 50 candidate strains with high propionic acid production. Among them, XA-2103 demonstrated significant functional superiority in both sequence and metabolic validation for high propionic acid production.Subsequent mechanistic studies and animal trials have both confirmed the excellent performance of the XA-2103 strain in restoring gut health.

Public information shows that Inflammatory Bowel Disease (IBD) is becoming a "silent killer" for global digestive health. Traditional treatment methods are often accompanied by risks of infection, secondary tumors, or high costs, and long-term use can easily lead to loss of response.In 2024, the National Health Commission of China, in collaboration with the National Development and Reform Commission, the National Medical Products Administration, and 14 other departments, officially launched the "Three-Year Action Plan for Intestinal Health Promotion," incorporating the tackling of IBD into the national comprehensive prevention and control strategy for chronic diseases.

In recent years, the Xbiome team has utilized cutting-edge AI+BT technologies to deeply explore research on strain functions and mechanisms. XA-2103 is another star strain from Xbiome to receive national patent authorization in a short time, following XA-1416 in May this year. Xbiome believes that with in-depth mechanism research and excellent experimental data, XA-2103 will provide a brand-new "probiotic solution" for improving intestinal health in China.Currently, Xbiome has established commercial partnerships with well-known probiotic, food, and beverage companies such as WonderLab, Mead Johnson China, and SciTech Biology. Several probiotic products containing the XA-2103 strain, from brands like Chayan Yuese and Health Express, have officially hit the market.

Relying on a vast strain library and an AI microbiome research and product development platform that combines "dry and wet" approaches, Xbiome can achieve full-process R&D from scientific foundational research, strain screening, and functional validation to commercial transformation, providing scientifically evidenced high-quality products and R&D solutions for probiotics and the broader health industry partners.

Note: The above content does not involve product efficacy promotion. It only cites the publicly available patent application materials for the purpose of providing a scientific introduction to the raw material strains.

Cited References: SONG, X., Shu, T., Zhang, S., Zhou, X., Zhang, Z., Wang, P., Hu, C., Pan, J., Dai, X., Tan, Y., Wu, X., Meng, H., Hao, H., & Xiao, G. (2024). Propionate-producing Probiotic Strains Attenuate Murine Colitis by Modulating Immune Response and Restoring the Intestinal Barrier. Frontiers in Nutrition.

-End-